8-K: AXT Reports Q2 2025 Financial Results Amid Revenue Decline and Export Permit Delays

AXT, Inc. announced its second quarter 2025 financial results, revealing a significant year-over-year revenue decrease and continued net losses, though gross margins showed recovery from the prior quarter's negative figures.

Summary

• Revenue for the second quarter of 2025 was $18.0 million, a decrease from $19.4 million in Q1 2025 and $27.9 million in Q2 2024.
• GAAP gross margin improved to 8.0% in Q2 2025, up from (6.4)% in Q1 2025, but significantly lower than 27.4% in Q2 2024.
• Non-GAAP gross margin was 8.2% in Q2 2025, compared to (6.1)% in Q1 2025 and 27.6% in Q2 2024.
• GAAP net loss for Q2 2025 was $7.0 million, or $0.16 per share, an improvement from $8.8 million ($0.20 per share) in Q1 2025, but worse than $1.5 million ($0.04 per share) in Q2 2024.
• Non-GAAP net loss was $6.4 million, or $0.15 per share, in Q2 2025, compared to $8.2 million ($0.19 per share) in Q1 2025 and $0.8 million ($0.02 per share) in Q2 2024.
• Substrate revenue increased sequentially but was less than expected due to longer processing times for gallium arsenide export permits and sluggish demand in China.
• Made good progress in recovering gross margins through focus on manufacturing process and efficiency.
• Observed healthy growth in AI-related demand for indium phosphide in China.
• Obtained first export permits for indium phosphide in June and shipped initial orders to customers outside of China.
• The STAR Market IPO application for its subsidiary, Tongmei, is still subject to review and approval by the CSRC and other authorities, with the company hoping to accomplish this goal in the coming months.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to significant year-over-year declines in revenue and increased net losses. While there was sequential improvement in gross margins and net loss, and some positive signs in AI-related demand and new export permits, these are overshadowed by ongoing export permit delays, sluggish China demand, and the prolonged STAR Market IPO process. The company's financial health has deteriorated significantly compared to the prior year.

Positives

• GAAP gross margin recovered significantly to 8.0% in Q2 2025 from a negative (6.4)% in Q1 2025.
• Non-GAAP gross margin also improved to 8.2% in Q2 2025 from a negative (6.1)% in Q1 2025.
• GAAP net loss improved sequentially to $7.0 million in Q2 2025 from $8.8 million in Q1 2025.
• Non-GAAP net loss improved sequentially to $6.4 million in Q2 2025 from $8.2 million in Q1 2025.
• Observed healthy growth in AI-related demand for indium phosphide in China.
• Obtained first export permits for indium phosphide in June, enabling initial shipments to customers outside of China.
• Competitive positioning is enhanced by superior product performance in key specifications like low etch pit density (EPD).

Negatives

• Revenue for Q2 2025 was $18.0 million, a significant decrease from $27.9 million in Q2 2024 and a sequential decline from $19.4 million in Q1 2025.
• GAAP gross margin of 8.0% in Q2 2025 is substantially lower than 27.4% in Q2 2024.
• Non-GAAP gross margin of 8.2% in Q2 2025 is substantially lower than 27.6% in Q2 2024.
• GAAP net loss of $7.0 million in Q2 2025 is significantly worse than the $1.5 million net loss in Q2 2024.
• Non-GAAP net loss of $6.4 million in Q2 2025 is significantly worse than the $0.8 million net loss in Q2 2024.
• Substrate revenue increase was less than expected due to longer processing times for gallium arsenide export permits.
• Sluggish demand environment in China negatively affected both substrate and raw material businesses.

Risks

• Requests for redemptions by private equity funds in China of investments in Tongmei.
• Administrative challenges in satisfying the requirements of various government agencies in China in connection with the listing of shares of Tongmei on the STAR Market.
• Continued open access to companies to list shares on the STAR Market.
• Investor enthusiasm for new listings of shares on the STAR Market.
• Geopolitical tensions between China and the United States.
• Timing and receipt of significant orders.
• Cancellation of orders and return of product.
• Emerging applications using chips or devices fabricated on company substrates.
• End-user acceptance of products containing chips or devices fabricated on company substrates.
• Ability to bring new products to market.
• Product announcements by competitors.
• Ability to control costs and improve efficiency.
• Ability to utilize manufacturing capacity.
• Product yields and their impact on gross margins.
• Relocation of manufacturing lines and ramping of production.
• Possible factory shutdowns as a result of air pollution in China or COVID-19.
• COVID-19 or other outbreaks of a contagious disease.
• Tariffs and other trade war issues.
• Financial performance of partially owned supply chain companies.
• Policies and regulations in China.

Future Outlook

The company anticipates continued progress in driving recovery in gross margins and is working diligently to support next-generation technology requirements for its global customer base. The STAR Market IPO for its subsidiary, Tongmei, is still subject to review and approval by the CSRC and other authorities, with the company hoping to accomplish this goal in the coming months. The company expects to see healthy growth in AI-related demand for indium phosphide and has begun shipping initial orders of indium phosphide substrates to customers outside of China after obtaining export permits.

Management Comments

• "Our substrate revenue increased in Q2 from the prior quarter, though the increase was less than we had expected as a result of longer processing times for gallium arsenide export permits, coupled with some sluggishness in the demand environment in China, which also affected our raw material business."
• "That said, we made good progress in driving recovery in our gross margins, with a strong focus on our manufacturing process and efficiency."
• "We also saw healthy growth in AI-related demand for indium phosphide in China and, as a result of obtaining our first export permits in June, were able to ship initial orders of indium phosphide substrates to customers outside of China."
• "Our competitive positioning continues to be enhanced by superior product performance in key specifications such as low etch pit density, or EPD, and we are working diligently to support the next-generation technology requirements of our global customer base."

Industry Context

AXT operates in the compound semiconductor wafer substrate market, a critical component for advanced technologies like 5G, AI, and data center connectivity, where typical silicon wafers are insufficient. The company's performance is influenced by global supply chain dynamics, particularly export regulations from China, and demand trends in key markets like China. The reported sluggish demand in China and delays in export permits highlight ongoing geopolitical and economic challenges impacting the semiconductor supply chain. The healthy growth in AI-related demand for indium phosphide suggests a positive niche within the broader market, aligning with the global surge in AI infrastructure development.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Experience significant dilution of earnings per share due to increased net losses and face uncertainty regarding the STAR Market IPO and geopolitical risks.
• Employees: Continued focus on manufacturing efficiency might imply operational adjustments, but no direct impact on employment is stated.
• Customers: Delays in gallium arsenide export permits could impact supply, while new indium phosphide export permits could improve supply for non-China customers. Superior product performance (low EPD) aims to meet next-generation technology requirements.
• Suppliers: Sluggish demand in China affecting the raw material business could impact suppliers, especially those partially owned by AXT in its supply chain.
• Creditors: Increased short-term loans from $47.264 million to $55.928 million indicate increased reliance on debt, which could be a concern if profitability does not improve.

Next Steps

• Continue driving recovery in gross margins through focus on manufacturing process and efficiency.
• Support next-generation technology requirements of the global customer base.
• Await review and approval by the CSRC and other authorities for Tongmei's STAR Market IPO, with the goal of accomplishing it in the coming months.
• Host a conference call on July 31, 2025, at 1:30 p.m. PT to discuss the results.

Key Dates

Recommendation

The company's Q2 2025 results show a significant year-over-year decline in revenue and increased net losses, indicating a challenging operating environment. While there are positive signs such as sequential gross margin recovery from negative territory, healthy AI-related indium phosphide demand, and the securing of initial export permits for indium phosphide outside China, these are counterbalanced by ongoing issues like gallium arsenide export permit delays, sluggish demand in China, and the prolonged uncertainty surrounding the Tongmei STAR Market IPO. The stock is speculative given the geopolitical risks and operational headwinds, but the strategic importance of compound semiconductors for emerging technologies like AI and 5G, coupled with the company's efforts to improve efficiency and expand market access, suggest potential for future recovery. For existing investors, holding might be warranted to see if these positive trends materialize and if the IPO proceeds. For new investors, the current financial performance and risks suggest caution, making a 'hold' a balanced approach rather than a 'buy' or 'sell' at this juncture.

Keywords

Compound Semiconductor, Wafer Substrates, Indium Phosphide, Gallium Arsenide, Germanium, AI, 5G Infrastructure, Data Center Connectivity, Silicon Photonics, Optoelectronic Devices, STAR Market IPO, China Export Permits, Semiconductor Manufacturing, Material Science